Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients
Implements a most-favored-nation pricing framework requiring pharmaceutical companies to sell drugs in the United States at prices no higher than the lowest price offered in comparable developed countries.
Section by Section
What each section does, and how they differ.
Directs HHS to achieve most-favored-nation pricing for prescription drugs aligned with prices in developed nations.
HHS shall facilitate direct-to-consumer and Medicare programs implementing MFN price targets.
Commerce and USTR to ensure foreign countries not engaged in practices forcing U.S. patients to subsidize global pharmaceutical R&D.
HHS to facilitate direct-to-consumer purchasing programs at MFN prices.
HHS to communicate MFN price targets to manufacturers within 30 days; pursue rulemaking and importation authority if progress stalls.